Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis.
Kroksveen, Ann C; Jaffe, Jacob D; Aasebø, Elise; Barsnes, Harald; Bjørlykke, Yngvild; Franciotta, Diego; Keshishian, Hasmik; Myhr, Kjell-Morten; Opsahl, Jill A; van Pesch, Vincent; Teunissen, Charlotte E; Torkildsen, Øivind; Ulvik, Rune J; Vethe, Heidrun; Carr, Steven A; Berven, Frode S.
; 15(19): 3361-9, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26152395
Deciphering the biochemistry and identifying biomarkers to multiple sclerosis.
Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis.
Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder.
Cerebrospinal fluid proteomics in multiple sclerosis.
Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.
Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.
The role of chromogranin B in an animal model of multiple sclerosis.
Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.
Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis.